AU2002345089A1 - Synthetic double stranded oligonucleotides for targeted inhibition of gene expression - Google Patents

Synthetic double stranded oligonucleotides for targeted inhibition of gene expression

Info

Publication number: AU2002345089A1
Authority: AU; Australia
Prior art keywords: gene expression; double stranded; stranded oligonucleotides; synthetic double; targeted inhibition
Prior art date: 2001-07-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

AU2002345089A

Other versions

AU2002345089B2 (en

Inventor

Niki Gunkel

Jochen Huber

Sandra Neumann

Eugen Uhlmann

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Aventis Deutschland GmbH

Original Assignee

Sanofi Aventis Deutschland GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-12

Filing date

2002-07-05

Publication date

2003-05-22

2001-07-12 Priority claimed from DE10133858A external-priority patent/DE10133858A1/en

2002-07-05 Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH

2003-05-22 Publication of AU2002345089A1 publication Critical patent/AU2002345089A1/en

2005-12-22 Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request for Assignment Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH

2007-04-05 Application granted granted Critical

2007-04-05 Publication of AU2002345089B2 publication Critical patent/AU2002345089B2/en

2022-07-05 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000014509 gene expression Effects 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1

AU2002345089A 2001-07-12 2002-07-05 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression Ceased AU2002345089B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10133858.9		2001-07-12
DE10133858A DE10133858A1 (en)	2001-07-12	2001-07-12	Synthetic double-stranded oligonucleotides for targeted inhibition of gene expression
PCT/EP2002/007480 WO2003008576A2 (en)	2001-07-12	2002-07-05	Synthetic double stranded oligonucleotides for targeted inhibition of gene expression

Publications (2)

Publication Number	Publication Date
AU2002345089A1 true AU2002345089A1 (en)	2003-05-22
AU2002345089B2 AU2002345089B2 (en)	2007-04-05

Family

ID=7691504

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002345089A Ceased AU2002345089B2 (en)	2001-07-12	2002-07-05	Synthetic double stranded oligonucleotides for targeted inhibition of gene expression

Country Status (14)

Country	Link
US (1)	US8772469B2 (en)
EP (1)	EP1409670B1 (en)
JP (1)	JP4643906B2 (en)
AT (1)	ATE484586T1 (en)
AU (1)	AU2002345089B2 (en)
CA (1)	CA2453301C (en)
CY (1)	CY1111645T1 (en)
DE (2)	DE10133858A1 (en)
DK (1)	DK1409670T3 (en)
ES (1)	ES2354062T3 (en)
IL (2)	IL159758A0 (en)
MX (1)	MXPA04000179A (en)
PT (1)	PT1409670E (en)
WO (1)	WO2003008576A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9096636B2 (en) *	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) *	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040266706A1 (en) *	2002-11-05	2004-12-30	Muthiah Manoharan	Cross-linked oligomeric compounds and their use in gene modulation
US20060009409A1 (en)	2002-02-01	2006-01-12	Woolf Tod M	Double-stranded oligonucleotides
EP2221377B2 (en)	2002-02-01	2017-05-17	Life Technologies Corporation	Oligonucleotide compositions with enhanced efficiency
EP1560840B1 (en)	2002-11-05	2015-05-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9827263B2 (en) *	2002-11-05	2017-11-28	Ionis Pharmaceuticals, Inc.	2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US9771578B2 (en) *	2002-11-05	2017-09-26	Ionis Pharmaceuticals, Inc.	Phosphorous-linked oligomeric compounds and their use in gene modulation
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
CA2568735A1 (en) *	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
US20100292301A1 (en) *	2007-02-28	2010-11-18	Elena Feinstein	Novel sirna structures
RU2010112771A (en) *	2007-10-09	2011-11-20	Коули Фармасьютикал ГмбХ (DE)	IMMUNITY MULATING ANALOGUES OF OLIGONUCLEOTIDES CONTAINING MODIFIED SUGAR GROUPS
WO2009090639A2 (en) *	2008-01-15	2009-07-23	Quark Pharmaceuticals, Inc.	Sirna compounds and methods of use thereof
EP3643782A1 (en)	2008-02-11	2020-04-29	Phio Pharmaceuticals Corp.	Modified rnai polynucleotides and uses thereof
WO2010008582A2 (en)	2008-07-18	2010-01-21	Rxi Pharmaceuticals Corporation	Phagocytic cell drug delivery system
CN108165548B (en)	2008-09-22	2022-10-14	菲奥医药公司	Reduced size self-delivering RNAi compounds
WO2010059226A2 (en)	2008-11-19	2010-05-27	Rxi Pharmaceuticals Corporation	Inhibition of map4k4 through rnai
WO2010078536A1 (en)	2009-01-05	2010-07-08	Rxi Pharmaceuticals Corporation	Inhibition of pcsk9 through rnai
US9745574B2 (en)	2009-02-04	2017-08-29	Rxi Pharmaceuticals Corporation	RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
CN103200945B (en)	2010-03-24	2016-07-06	雷克西制药公司	RNA interference in ocular syndromes
US9080171B2 (en)	2010-03-24	2015-07-14	RXi Parmaceuticals Corporation	Reduced size self-delivering RNAi compounds
KR102453078B1 (en)	2010-03-24	2022-10-11	피오 파마슈티칼스 코프.	Rna interference in dermal and fibrotic indications
CN113151180A (en)	2013-12-02	2021-07-23	菲奥医药公司	Immunotherapy of cancer
CA2947270A1 (en)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treating cancer using nucleic acids targeting mdm2 or mycn
KR102689262B1 (en)	2014-09-05	2024-07-30	피오 파마슈티칼스 코프.	Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
EP3862005A1 (en)	2015-07-06	2021-08-11	Phio Pharmaceuticals Corp.	Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US10808247B2 (en)	2015-07-06	2020-10-20	Phio Pharmaceuticals Corp.	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US11021707B2 (en)	2015-10-19	2021-06-01	Phio Pharmaceuticals Corp.	Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
MA45328A (en)	2016-04-01	2019-02-06	Avidity Biosciences Llc	NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
MA45470A (en)	2016-04-01	2019-02-06	Avidity Biosciences Llc	KRAS NUCLEIC ACIDS AND THEIR USES
MA45469A (en)	2016-04-01	2019-02-06	Avidity Biosciences Llc	BETA-CATENIN NUCLEIC ACIDS AND THEIR USES
MA45349A (en)	2016-04-01	2019-02-06	Avidity Biosciences Llc	EGFR NUCLEIC ACIDS AND THEIR USES
CN118667812A (en)	2017-12-06	2024-09-20	艾维迪提生物科学公司	Compositions and methods for treating muscular atrophy and tonic muscular dystrophy
EP4041248A4 (en) *	2019-10-11	2024-03-20	Alnylam Pharmaceuticals Inc.	MODIFIED OLIGONUCLEOTIDES
EP4121063A4 (en)	2020-03-19	2024-07-03	Avidity Biosciences, Inc.	Compositions and methods of treating facioscapulohumeral muscular dystrophy
US20250304957A1 (en) *	2022-05-13	2025-10-02	Alnylam Pharmaceuticals, Inc.	Single-stranded loop oligonucleotides
WO2024238385A2 (en) *	2023-05-12	2024-11-21	Alnylam Pharmaceuticals, Inc.	Single-stranded loop oligonucleotides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3717436A1 (en) *	1987-05-23	1988-12-08	Hoechst Ag	METHOD FOR PRODUCING DOUBLE-STRANDED DNA
US4924624A (en)	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US6033909A (en) *	1992-01-22	2000-03-07	Hoechst Aktiengesellschaft	Oligonucleotide analogs, their preparation and use
WO1994001550A1 (en) *	1992-07-02	1994-01-20	Hybridon, Inc.	Self-stabilized oligonucleotides as therapeutic agents
US5646042A (en) *	1992-08-26	1997-07-08	Ribozyme Pharmaceuticals, Inc.	C-myb targeted ribozymes
US5583032A (en) *	1992-10-21	1996-12-10	The Cleveland Clinic Foundation And National Institutes Of Health	Method of cleaving specific strands of RNA
US5532130A (en) *	1993-07-20	1996-07-02	Dyad Pharmaceutical Corporation	Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
US5886165A (en) *	1996-09-24	1999-03-23	Hybridon, Inc.	Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US6794499B2 (en) *	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
US6004804A (en) *	1998-05-12	1999-12-21	Kimeragen, Inc.	Non-chimeric mutational vectors
US6010907A (en) *	1998-05-12	2000-01-04	Kimeragen, Inc.	Eukaryotic use of non-chimeric mutational vectors
AU5314999A (en) *	1998-07-14	2000-02-07	Isis Pharmaceuticals, Inc.	Modified oligonucleotides
AU3369900A (en)	1999-02-19	2000-09-04	General Hospital Corporation, The	Gene silencing
US6316194B1 (en) *	1999-12-16	2001-11-13	Ribotargets	Methods and kits for discovery of RNA-binding antimicrobials
RU2322500C2 (en) *	2000-12-01	2008-04-20	Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф.	Small rna molecules mediating rna interference

2001
- 2001-07-12 DE DE10133858A patent/DE10133858A1/en not_active Withdrawn
2002
- 2002-07-05 AU AU2002345089A patent/AU2002345089B2/en not_active Ceased
- 2002-07-05 IL IL15975802A patent/IL159758A0/en unknown
- 2002-07-05 AT AT02743264T patent/ATE484586T1/en active
- 2002-07-05 DK DK02743264.0T patent/DK1409670T3/en active
- 2002-07-05 WO PCT/EP2002/007480 patent/WO2003008576A2/en not_active Ceased
- 2002-07-05 EP EP02743264A patent/EP1409670B1/en not_active Expired - Lifetime
- 2002-07-05 PT PT02743264T patent/PT1409670E/en unknown
- 2002-07-05 JP JP2003514893A patent/JP4643906B2/en not_active Expired - Fee Related
- 2002-07-05 ES ES02743264T patent/ES2354062T3/en not_active Expired - Lifetime
- 2002-07-05 CA CA2453301A patent/CA2453301C/en not_active Expired - Fee Related
- 2002-07-05 DE DE50214715T patent/DE50214715D1/en not_active Expired - Lifetime
- 2002-07-05 MX MXPA04000179A patent/MXPA04000179A/en active IP Right Grant
- 2002-07-11 US US10/193,747 patent/US8772469B2/en not_active Expired - Fee Related
2004
- 2004-01-07 IL IL159758A patent/IL159758A/en not_active IP Right Cessation
2011
- 2011-01-04 CY CY20111100021T patent/CY1111645T1/en unknown

Publication	Publication Date	Title
AU2002345089A1 (en)	2003-05-22	Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
AU2002329667A1 (en)	2003-02-17	Specific inhibition of gene expression by small double stranded rnas
WO2003008576A3 (en)	2003-10-23	Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
HUP0103571A3 (en)	2006-01-30	Characterisation of gene function using double stranded rna inhibition
AU2002339348A1 (en)	2003-07-03	Inhibition of STAT-1
AU2002251266A1 (en)	2002-10-28	Inhibitors of akt activity
AU2002259196A1 (en)	2003-03-03	Gene expression profiling
AU2002253836A1 (en)	2002-08-19	Aptamer-mediated regulation of gene expression
AU2003297474A1 (en)	2004-07-14	Methods of inhibiting gene expression by rna interference
AU2003287254A1 (en)	2004-05-25	Inhibition of gene expression using rna interfering agents
AU2003299864A1 (en)	2004-07-29	Sirna compounds and methods for the downregulation of gene expression
AU2002314997A1 (en)	2002-12-16	Methods for low background cloning of dna using long oligonucleotides
AU2001237992A1 (en)	2001-08-07	Purification of oligonucleotides
AU2003222197A1 (en)	2003-09-02	Inhibition of rna function
AU1548401A (en)	2001-06-04	Use of disease-associated gene
AU2003239864A1 (en)	2003-12-12	Antisense moodulation of kinesin-like 1 expression
AU2003272498A1 (en)	2004-04-08	Fragmentation of dna
AU2003282564A1 (en)	2004-05-04	Gene profiling of single or multiple cells
AU2003285583A1 (en)	2004-06-30	Oligonucleotide guided analysis of gene expression
AU2002360394A1 (en)	2003-06-10	Facilitation of rna interference
AU2002325305A1 (en)	2003-05-22	Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression
AU2002219992A1 (en)	2002-06-11	Targeted regulation of gene expression
AU2003253197A1 (en)	2004-02-25	Targeted gene modification by single-stranded dna oligonucleotides
AU2002345658A1 (en)	2002-12-23	Methods for targeted expression of therapeutic nucleic acid
AU2003256931A1 (en)	2004-02-16	USES OF CIRCADIAN GENE mPER2